Everest Medicines Ltd. · HKEX:1952
Everest Medicines — H1 2024 Earnings Presentation
26 slides from Everest Medicines's earnings presentation, August 2024
Slide 1: Better Medicines, Better Life: 2024 Interim Earnings Deck
Better Medicines, Better Life 2024 Interim Earnings Deck August 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Everest Medicines Limited (the “Company” and together with its subsidiaries, the “Group”) solely for information purposes and does not constitute a recommendation regarding the securities of the Group or an offer to sell or issue or the solicitation
Slide 3: 1H 2024: Solid Revenue Growth with Focus on Operating Efficiency and Strong Balance Sheet
1H 2024: Solid Revenue Growth with Focus on Operating Efficiency and Strong Balance Sheet Substantial High gross Notably improved Significantly Strong cash revenue growth margin1 cost efficiency2 narrowed non- balance as % of revenue Operating expenses as % of IFRS net loss3 revenue +158% vs.2H 2023
Slide 4: Fully Integrated Biopharma: Dual Engine Strategy to Value Creation
Fully Integrated Biopharma: Dual Engine Strategy to Value Creation In-licensing Differentiated portfolio drives commercial cash flow Leverage commercial platform to maximize synergies • Drive organic revenue growth • Expand pipeline in core therapeutic areas and increase scale and efficiency Pipelin
Slide 5: Strong Sales Growth Driven by NEFECON and XERAVA, Reiterate Full Year Revenue Guidance
Strong Sales Growth Driven by NEFECON® and XERAVA®, Reiterate Our Full Year Revenue Guidance Product revenue (RMB m) +158% Launched in May Continued revenue 301.5 2024 ramp up 167.3M 134.2M 117.0 2H 2023 1H 2024 On track for the full year revenue guidance of 700m RMB 5
Slide 6: 1H 2024 Major Regulatory and Clinical Achievements
1H 2024 Major Regulatory and Clinical Achievements Assets with Zetomipzomib global rights • Singapore Approval • Eravacycline clinical • Macau Approval • First Chinese patient • mRNA personalized breakpoint approved dosed in global Phase cancer vaccine IIT trial • Hong Kong Approval by ChinaCAST • S
Slide 7: Significant Unmet Medical Needs in IgAN Addressed by NEFECON
Significant Unmet Medical Needs in IgAN Addressed by NEFECON® Substantial unmet medical needs in China No approved therapy prior to NEFECON® Current treatment options, such as RAS inhibitors, are 5M non-targeted and used off-label IgAN Patients Current treatment options do not alter disease progress
Slide 8: Successful Commercial Launch of NEFECON in China
Successful Commercial Launch of NEFECON® in China Successful commercial launch in China by leveraging online and offline innovative approaches Online Traditional prescription hospitals Focused and highly efficient commercial organization ~120 sales representatives ~500 hospitals >60% of market poten
Slide 9: Significant Unmet Clinical Needs and Limited Therapeutic Options for MDR Infections
Significant Unmet Clinical Needs and Limited Therapeutic Options for MDR Infections Substantial unmet medical needs in China Current treatment options cannot fully meet clinical needs Low tissue concentration, High carbapenem resistance rates Tigecycline adverse events, Black Box warning (all-cause
Slide 10: XERAVA Revenue Continues to Grow by Expanding and Deepening Hospital Coverage
XERAVA® Revenue Continues to Grow by Expanding and Deepening Hospital Coverage Sales reps ~120 Target hospitals ~300 1 Medical publications 5 New guideline inclusions 3 Core market Treated patients increased by ~300% vs. 2023 2H Non-core market: Hospital listing increased by ~75% vs. 2023 2H CSO par
Slide 11: Etrasimod: Approved in Macau and Expected to Launch in Greater Bay Area in 2H 2024
Etrasimod: Approved in Macau and Expected to Launch in Greater Bay Area in 2H 2024 19 Designated medical institutions in Guangdong approved to use clinically urgently needed drugs that have been marketed in Hong Kong and Macau Effective, oral advanced UC treatment well-suited Large medical needs in
Slide 12: Pursuing Asian Leadership Position in Blue Ocean Therapeutic Areas
Pursuing Asian Leadership Position in “Blue Ocean” Therapeutic Areas To be a leading biopharma in Asia Pacific by 2030, we aim to create social impact through our Vision innovative medicine portfolio and sustainable growth. 3 core therapeutic areas with 4 near term products aggregated peak sales pot
Slide 13: Revenue to Ramp Up Significantly with the Launch of Near Term Products in China
Revenue to Ramp Up Significantly with the Launch of 4 Near Term Products in China in RMB Peak sales of RMB 10B+ Cefepime- taniborbactam 4 approved BIC/FIC products 3 focused TAs 700M 126M 2023 2024E 2025E and beyond 13
Slide 14: Pipeline of Products in Our Therapeutic Area Focus of Renal Diseases
Pipeline of Products in Our Therapeutic Area Focus of Renal Diseases • The clinical pipeline for the treatment of renal diseases are expected to bring new treatment options to ~10M patients with glomerular disease Focal Segmental Minimal Change Glomerulosclerosis Disease (FSGS) Membranous (MCD) 500K
Slide 15: Complementary Products in Our Therapeutic Area Focus of MDR Infection Treatment
Complementary Products in Our Therapeutic Area Focus of MDR Infection Treatment (Eravacycline) Cefepime-taniborbactam EVER206 (SPR206) First-in-class fluorocycline Best-in-class BL/BLI, with potent antibiotic, broad spectrum and selective inhibitory activity A novel polymyxin derivative with coverag
Slide 16: Dual Engine Approach Towards Building Differentiated Future Pipeline
Dual Engine Approach Towards Building Differentiated Future Pipeline In-licensing Discovery Focus on core therapeutic areas Clinically validated mRNA platform In our focused TAs Focus on late-stage and commercial-stage assets Therapeutic cancer vaccines Focus on commercial and clinical Focus on deli
Slide 17: A Growing Pipeline of Assets with Global Rights
A Growing Pipeline of Assets with Global Rights mRNA platform Personalized Immune- EVER001 cancer TAA cancer modulatory In vivo CAR-T (BTKi) vaccines vaccines cancer vaccines Cancer Indication Membranous Cancer Cancer Cancer /Autoimmune Nephropathy Development Phase 1b data Launched IIT US IND submi
Slide 18: EVER001: A Potent Covalent Reversible BTK Inhibitor Suited for Autoimmune Renal Indications
EVER001: A Potent Covalent Reversible BTK inhibitor Suited for Autoimmune Renal Indications Compared with covalent and irreversible BTK inhibitors, EVER001 is potentially BIC with high selectivity while maintaining high potency Large unmet medical needs globally EVER001 1 Reversible covalency 2 Exce
Slide 19: EVER001: Phase 1b Trial Ongoing and Preliminary Data Expected in 2H 2024
EVER001: Phase 1b Trial Ongoing and Preliminary Data Expected in 2H 2024 Phase 1 results in healthy subjects ✓ EVER001 was generally well-tolerated after single or multiple exposures to healthy subjects, no serious adverse events were reported ✓ EVER001 exhibited a dose-proportional increase in Cmax
Slide 20: A Fully Integrated and Clinically Validated mRNA Platform
A Fully Integrated and Clinically Validated mRNA Platform Proprietary antigen Proprietary LNP CMC process Self-owned design algorithm delivery system development manufacturing facility ensures high leads to enhanced ensures robust (Jiashan, Zhejiang) expression of target T cell immunity mRNA DS/DP s
Slide 21: EVM16: A Personalized Neoantigen Cancer Vaccine
EVM16: A Personalized Neoantigen Cancer Vaccine Based on Specific Mutations of Cancer Patients Everest Proprietary Neoantigen Prediction Algorithm MHC binding strength/number Differential Epitope/peptide binding immunogenicity Pathogen seq score similarity WT/MT seq EVM16 … change distance MHC I and
Slide 22: EVM14: An Off-the-Shelf Tumor Associated Antigen (TAA) Vaccine
EVM14: An Off-the-Shelf Tumor Associated Antigen (TAA) Vaccine Advantages of TAA cancer vaccine Good tumor specificity (tumor vs. normal) More T cell epitopes and no HLA restriction Off-the-shelf, well suited for advanced disease Reduced manufacture costs (vs. PCV) Potential for multiple cancer indi
Slide 23: Income Statement and Cash Position
Income Statement and Cash Position For the Six Months Revenue increased by RMB292.6 million to RMB301.5 million, primarily due to combined effect of continued Ended 30 June expansion of Xerava® sales in mainland China and Hong Kong, and the launch of Nefecon® in mainland China and Singapore. RMB’000
Slide 24: Our Priorities in 2H 2024
Our Priorities in 2H 2024 Doctor and patient education, NRDL negotiation, and treatment guideline inclusion Deepen core market penetration and expand CSO partnership Priorities Commercialization in Greater Bay Area, and China NDA submission In-house R&D progress in mRNA therapeutic vaccines Results
Slide 25: 1H 2024: Solid Revenue Growth with Focus on Operating Efficiency and Strong Balance Sheet
1H 2024: Solid Revenue Growth with Focus on Operating Efficiency and Strong Balance Sheet Substantial High gross Notably improved Significantly Strong cash revenue growth margin1 cost efficiency2 narrowed non- balance as % of revenue Operating expenses as % of IFRS net loss3 revenue +158% vs.2H 2023
Slide 26: Q&A Contact Us
Q&A CONTACT US: IR@everestmedicines.com